661 related articles for article (PubMed ID: 31585938)
1. Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G; Mezquita L; Facchinetti F; Planchard D; Gazzah A; Bigot L; Rizvi AZ; Frias RL; Thiery JP; Scoazec JY; Sourisseau T; Howarth K; Deas O; Samofalova D; Galissant J; Tesson P; Braye F; Naltet C; Lavaud P; Mahjoubi L; Abou Lovergne A; Vassal G; Bahleda R; Hollebecque A; Nicotra C; Ngo-Camus M; Michiels S; Lacroix L; Richon C; Auger N; De Baere T; Tselikas L; Solary E; Angevin E; Eggermont AM; Andre F; Massard C; Olaussen KA; Soria JC; Besse B; Friboulet L
Clin Cancer Res; 2020 Jan; 26(1):242-255. PubMed ID: 31585938
[TBL] [Abstract][Full Text] [Related]
2. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Okada K; Araki M; Sakashita T; Ma B; Kanada R; Yanagitani N; Horiike A; Koike S; Oh-Hara T; Watanabe K; Tamai K; Maemondo M; Nishio M; Ishikawa T; Okuno Y; Fujita N; Katayama R
EBioMedicine; 2019 Mar; 41():105-119. PubMed ID: 30662002
[TBL] [Abstract][Full Text] [Related]
3. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
4. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
[No Abstract] [Full Text] [Related]
5. Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
Redaelli S; Ceccon M; Zappa M; Sharma GG; Mastini C; Mauri M; Nigoghossian M; Massimino L; Cordani N; Farina F; Piazza R; Gambacorti-Passerini C; Mologni L
Cancer Res; 2018 Dec; 78(24):6866-6880. PubMed ID: 30322862
[TBL] [Abstract][Full Text] [Related]
6. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound
Yoda S; Lin JJ; Lawrence MS; Burke BJ; Friboulet L; Langenbucher A; Dardaei L; Prutisto-Chang K; Dagogo-Jack I; Timofeevski S; Hubbeling H; Gainor JF; Ferris LA; Riley AK; Kattermann KE; Timonina D; Heist RS; Iafrate AJ; Benes CH; Lennerz JK; Mino-Kenudson M; Engelman JA; Johnson TW; Hata AN; Shaw AT
Cancer Discov; 2018 Jun; 8(6):714-729. PubMed ID: 29650534
[TBL] [Abstract][Full Text] [Related]
7.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
8. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
9. Treatment with Next-Generation ALK Inhibitors Fuels Plasma
Dagogo-Jack I; Rooney M; Lin JJ; Nagy RJ; Yeap BY; Hubbeling H; Chin E; Ackil J; Farago AF; Hata AN; Lennerz JK; Gainor JF; Lanman RB; Shaw AT
Clin Cancer Res; 2019 Nov; 25(22):6662-6670. PubMed ID: 31358542
[TBL] [Abstract][Full Text] [Related]
10. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
11. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Makimoto G; Ohashi K; Tomida S; Nishii K; Matsubara T; Kayatani H; Higo H; Ninomiya K; Sato A; Watanabe H; Kano H; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Toyooka S; Takata M; Maeda Y; Kiura K
J Thorac Oncol; 2019 Nov; 14(11):2009-2018. PubMed ID: 31374369
[TBL] [Abstract][Full Text] [Related]
12. A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
Sharma GG; Cortinovis D; Agustoni F; Arosio G; Villa M; Cordani N; Bidoli P; Bisson WH; Pagni F; Piazza R; Gambacorti-Passerini C; Mologni L
J Thorac Oncol; 2019 Nov; 14(11):e257-e259. PubMed ID: 31668326
[No Abstract] [Full Text] [Related]
13. Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.
Taniguchi H; Akagi K; Dotsu Y; Yamada T; Ono S; Imamura E; Gyotoku H; Takemoto S; Yamaguchi H; Sen T; Yano S; Mukae H
Cancer Sci; 2023 Jan; 114(1):164-173. PubMed ID: 36086904
[TBL] [Abstract][Full Text] [Related]
14. Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.
Ma X; Zhang K; Xu J; Gao H; Yang S; Qin H; Wang H; Gao F; Liu X
Thorac Cancer; 2023 Jul; 14(20):1980-1990. PubMed ID: 37265111
[TBL] [Abstract][Full Text] [Related]
15. Lorlatinib for the treatment of
Choo JR; Soo RA
Expert Rev Anticancer Ther; 2020 Apr; 20(4):233-240. PubMed ID: 32186215
[No Abstract] [Full Text] [Related]
16. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Xie B; Qiu Y; Zhou J; Du D; Ma H; Ji J; Zhu L; Zhang W
Clin Transl Oncol; 2022 Nov; 24(11):2231-2240. PubMed ID: 35852680
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of
Fukuda K; Takeuchi S; Arai S; Katayama R; Nanjo S; Tanimoto A; Nishiyama A; Nakagawa T; Taniguchi H; Suzuki T; Yamada T; Nishihara H; Ninomiya H; Ishikawa Y; Baba S; Takeuchi K; Horiike A; Yanagitani N; Nishio M; Yano S
Cancer Res; 2019 Apr; 79(7):1658-1670. PubMed ID: 30737231
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P
Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
